Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048864329> ?p ?o ?g. }
- W3048864329 abstract "Background: Membranous Nephropathy (MN) is a rare autoimmune disease related to PLA2R1 antibodies in 70% of cases. One third of patients enter in spontaneous remission. PLA2R1 epitopes in MN have been characterized in four different domains of PLA2R1 and a mechanism of epitope spreading from the immunodominant CysR domain to CTLD1 and/or CTLD7 and/or CTLD8 domains has been associated with poor prognosis. Epitope spreading could predict spontaneous remission (45% in non-spreader patients vs. 0.05% in spreader patients). The comparison of different regimens of rituximab dosing showed that: (i) early remission rate depends on rituximab dosing, (ii) low dose could be enough for patients with anti-PLA2R1 activity restricted to CysR, (iii) high dose may be required for spreader patients. This study aims to evaluate the efficacy of personalized treatment in PLA2R1-related MN depending on the epitope spreading status, in comparison to the established GEMRITUX protocol. Methods: A multicenter, randomized, controlled, prospective clinical trial will be conducted in 22 French hospitals. Sixty-four consecutive patients with PLA2R1-related MN will be randomly assigned to either the control group following the GEMRITUX protocol (symptomatic treatment for 6 months, if the nephrotic syndrome (NS) persists at month-6, two 375 mg/m2 rituximab infusions at 1 week interval) or the personalized treatment group (patients with no epitope spreading at month-0 will be treated with symptomatic treatment for 6 months, if NS persists at month-6, two 375 mg/m2 rituximab infusions at 1 week interval; patients with epitope spreading at month-0 or month-6 with persistent NS will be treated immediately with two 1 g rituximab infusions at 2 week interval). The primary study outcome is the rate of clinical remission at month-12. The secondary outcomes include complete and partial remissions, immunological remissions, relapses, proteinuria, albuminuria, serum creatinine, eGFR, PLA2R1 antibody titers, severe infections, lymphocyte counts and lymphocyte phenotype, residual rituximab levels at month-3 and neutralizing anti-rituximab antibodies at month-6 and month-12 after rituximab treatment. Discussion: The results of this trial will confirm whether personalized treatment of PLA2R1-driven nephrotic MN is more efficient to induce clinical remission than the established GEMRITUX protocol, and may thus contribute to improved remission rates and reduced relapse rates. Trial registration: NCT03804359 trial number. Registered on 15th January 2019." @default.
- W3048864329 created "2020-08-18" @default.
- W3048864329 creator A5001827578 @default.
- W3048864329 creator A5006830326 @default.
- W3048864329 creator A5028610566 @default.
- W3048864329 creator A5056387938 @default.
- W3048864329 creator A5060086678 @default.
- W3048864329 creator A5079452241 @default.
- W3048864329 creator A5080660015 @default.
- W3048864329 date "2020-08-13" @default.
- W3048864329 modified "2023-09-24" @default.
- W3048864329 title "Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial" @default.
- W3048864329 cites W1668085700 @default.
- W3048864329 cites W1986167294 @default.
- W3048864329 cites W1993067667 @default.
- W3048864329 cites W2004034968 @default.
- W3048864329 cites W2011340006 @default.
- W3048864329 cites W2011460189 @default.
- W3048864329 cites W2018459774 @default.
- W3048864329 cites W2024966589 @default.
- W3048864329 cites W2034759249 @default.
- W3048864329 cites W2047072740 @default.
- W3048864329 cites W2083760961 @default.
- W3048864329 cites W2089123887 @default.
- W3048864329 cites W2089916413 @default.
- W3048864329 cites W2097148864 @default.
- W3048864329 cites W2099314298 @default.
- W3048864329 cites W2122581834 @default.
- W3048864329 cites W2133344401 @default.
- W3048864329 cites W2141219630 @default.
- W3048864329 cites W2145486852 @default.
- W3048864329 cites W2146924887 @default.
- W3048864329 cites W2149055576 @default.
- W3048864329 cites W2158479143 @default.
- W3048864329 cites W2158873077 @default.
- W3048864329 cites W2166822765 @default.
- W3048864329 cites W2232005825 @default.
- W3048864329 cites W2470335436 @default.
- W3048864329 cites W2611534884 @default.
- W3048864329 cites W2767487300 @default.
- W3048864329 cites W2926905602 @default.
- W3048864329 cites W2962703330 @default.
- W3048864329 cites W2977665112 @default.
- W3048864329 cites W2994706881 @default.
- W3048864329 cites W2995133866 @default.
- W3048864329 cites W2995516475 @default.
- W3048864329 cites W2996827211 @default.
- W3048864329 cites W3000705808 @default.
- W3048864329 doi "https://doi.org/10.3389/fmed.2020.00412" @default.
- W3048864329 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7438577" @default.
- W3048864329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32903623" @default.
- W3048864329 hasPublicationYear "2020" @default.
- W3048864329 type Work @default.
- W3048864329 sameAs 3048864329 @default.
- W3048864329 citedByCount "6" @default.
- W3048864329 countsByYear W30488643292021 @default.
- W3048864329 countsByYear W30488643292022 @default.
- W3048864329 countsByYear W30488643292023 @default.
- W3048864329 crossrefType "journal-article" @default.
- W3048864329 hasAuthorship W3048864329A5001827578 @default.
- W3048864329 hasAuthorship W3048864329A5006830326 @default.
- W3048864329 hasAuthorship W3048864329A5028610566 @default.
- W3048864329 hasAuthorship W3048864329A5056387938 @default.
- W3048864329 hasAuthorship W3048864329A5060086678 @default.
- W3048864329 hasAuthorship W3048864329A5079452241 @default.
- W3048864329 hasAuthorship W3048864329A5080660015 @default.
- W3048864329 hasBestOaLocation W30488643291 @default.
- W3048864329 hasConcept C126322002 @default.
- W3048864329 hasConcept C141071460 @default.
- W3048864329 hasConcept C159654299 @default.
- W3048864329 hasConcept C168563851 @default.
- W3048864329 hasConcept C195616568 @default.
- W3048864329 hasConcept C203014093 @default.
- W3048864329 hasConcept C2775946357 @default.
- W3048864329 hasConcept C2777288759 @default.
- W3048864329 hasConcept C2778930706 @default.
- W3048864329 hasConcept C2779561371 @default.
- W3048864329 hasConcept C2780091579 @default.
- W3048864329 hasConcept C2780653079 @default.
- W3048864329 hasConcept C71924100 @default.
- W3048864329 hasConcept C90924648 @default.
- W3048864329 hasConceptScore W3048864329C126322002 @default.
- W3048864329 hasConceptScore W3048864329C141071460 @default.
- W3048864329 hasConceptScore W3048864329C159654299 @default.
- W3048864329 hasConceptScore W3048864329C168563851 @default.
- W3048864329 hasConceptScore W3048864329C195616568 @default.
- W3048864329 hasConceptScore W3048864329C203014093 @default.
- W3048864329 hasConceptScore W3048864329C2775946357 @default.
- W3048864329 hasConceptScore W3048864329C2777288759 @default.
- W3048864329 hasConceptScore W3048864329C2778930706 @default.
- W3048864329 hasConceptScore W3048864329C2779561371 @default.
- W3048864329 hasConceptScore W3048864329C2780091579 @default.
- W3048864329 hasConceptScore W3048864329C2780653079 @default.
- W3048864329 hasConceptScore W3048864329C71924100 @default.
- W3048864329 hasConceptScore W3048864329C90924648 @default.
- W3048864329 hasFunder F4320322807 @default.
- W3048864329 hasLocation W30488643291 @default.
- W3048864329 hasLocation W30488643292 @default.
- W3048864329 hasLocation W30488643293 @default.
- W3048864329 hasOpenAccess W3048864329 @default.